Drug Trial Radar · NCT06326060
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Mar 18, 2024
Primary completion
Apr 10, 2025
Study completion May 1, 2025
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Mar 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Conditions
- Obesity
Interventions
NNC0519-0130Drug
NNC0519-0130 will be administered subcutaneously.
PlaceboDrug
Placebo will be administered subcutaneously.
TirzepatideDrug
Tirzepatide will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative change in body weightTime frame: From baseline (week 0) to end of treatment (week 36)
Locations
70 sites in 3 countries. Site status is shown where the registry gives one.
Centricity Research-Arizona
Mesa, Arizona
Arkansas Clinical Research
Little Rock, Arkansas
Unity Health-Searcy Medical Center
Searcy, Arkansas
FDRC
Costa Mesa, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
UCLA Health Southbay Endocrine
Torrance, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Univ of Colorado at Denver
Aurora, Colorado
Nature Coast Clinical Research
Crystal River, Florida
Northeast Research Institute
Fleming Island, Florida
Jacksonville Ctr For Clin Res
Jacksonville, Florida
South Broward Research LLC
Miramar, Florida
Cedar-Crosse Research Center
Chicago, Illinois
Midwest Inst For Clin Res
Indianapolis, Indiana
Velocity Clin. Res Valparaiso
Valparaiso, Indiana
L-MARC Research Center
Louisville, Kentucky
Centennial Medical Group
Columbia, Maryland
StudyMetrix Research LLC
City of Saint Peters, Missouri
NYU Bariatric Surgical Ctr
New York, New York
Rochester Clinical Research, Inc.
Rochester, New York
Velocity Clinical Res. Inc Vestal
Vestal, New York
Medication Mgmnt, LLC_Grnsboro
Greensboro, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Physicians East Endocrinology
Greenville, North Carolina
Piedmont Healthcare Statesville
Statesville, North Carolina
Piedmont Healthcare/Research
Statesville, North Carolina
Accellacare
Wilmington, North Carolina
Velocity Clinical Res
Cleveland, Ohio
Remington Davis Inc
Columbus, Ohio
Providence Health Partners Ctr
Dayton, Ohio
Centricity Research - Ohio
Dublin, Ohio
Family Practice Center of Wadsworth Inc.
Wadsworth, Ohio
Lynn Institute of Norman
Norman, Oklahoma
The University of Penn Center
Philadelphia, Pennsylvania
Preferred Primary Care Physicians_Pittsburgh
Pittsburgh, Pennsylvania
Velocity Clin Res Providence
East Greenwich, Rhode Island
Medical University Of South Carolina
Charleston, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
Holston Medical Group Pc
Bristol, Tennessee
Baylr Sctt White Rs Inst, Endo
Dallas, Texas
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.